SMB collaboration
Dutch companies Batavia Bioservices and Xendo have announced a strategic business collaboration providing Batavia Bioservices with access to Xendo?s simulated moving bed purification technology.
Dutch companies Batavia Bioservices and Xendo have announced a strategic business collaboration providing Batavia Bioservices with access to Xendo’s simulated moving bed purification technology. All bioprocess activities of Xendo have been transferred and the company will also provide infrastructure, knowledge and experience in microbial process and product development.
Menzo Havenga, CEO of Batavia Bioservices, explains: "It is fully expected that our collaboration will result in more customers being offered a complete development services package.”
The companies have also announced that they will also establish joint marketing efforts whereby Xendo BV will provide engineering, regulatory and clinical support services and Batavia Bioservices will provide process development and analytical services.
André van de Sande, CEO of Xendo, adds, “I trust that by combining our forces both companies are better positioned to service our customers. This helps Xendo, both in the Netherlands and internationally, to further expand."
For more information on the companies, visit their websites at www.bataviabioservices.com and www.xendo.com
RAFA 2024: Michel Suman Discusses Food Safety And Authenticity Research
November 28th 2024During RAFA 2024, Michel Suman of Barilla Spa and Catholic University Sacred Heart talked with us about his food safety and authenticity research, focusing on contaminants, adulterants, and authenticity markers in food processing.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
In Conversation with the EAS Award Winner for Outstanding Achievements in Mass Spectrometry
November 27th 2024As part of our EAS 2024 coverage, we recently interviewed Benjamin Garcia of the Washington University in St. Louis about his work and his being awarded the EAS Award for Outstanding Achievements in Mass Spectrometry.
Innovative cryogen-free ambient air monitoring of trace-level air toxics at high humidity
November 27th 2024This application note presents an advanced analytical system for the sensitive detection of trace-level air toxics in humid ambient air samples, in accordance with US EPA Method TO-15A. The cryogen-free preconcentration and thermal desorption approach, coupled to GC-MS, delivers exceptional chromatographic performance even for highly volatile and polar compounds. The system meets the stringent detection limit requirements of the latest air monitoring regulations, with method detection limits as low as 0.7 pptv. This innovative analytical solution provides a robust, cost-effective platform for the reliable quantification of hazardous air pollutants, enabling compliance with regulatory standards.
